{"id":"NCT04688164","sponsor":"Relmada Therapeutics, Inc.","briefTitle":"A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment of Major Depressive Disorder (The RELIANCE-I Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-01-08","primaryCompletion":"2022-11-01","completion":"2022-11-10","firstPosted":"2020-12-29","resultsPosted":"2024-03-26","lastUpdate":"2024-08-27"},"enrollment":227,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"REL-1017","otherNames":["esmethadone"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"REL-1017","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder. Study participants will continue to take their current antidepressant therapy in addition to the study drug or placebo for the duration of the treatment period.","primaryOutcome":{"measure":"Change in the MADRS10 Total Score From Baseline to Day 28","timeFrame":"Day 28","effectByArm":[{"arm":"REL-1017 25 mg","deltaMin":-15.1,"sd":11.3},{"arm":"Placebo","deltaMin":-12.9,"sd":10.4}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":11,"countries":["United States"]},"refs":{"pmids":["38917366"],"seeAlso":["http://reliancestudies.com"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":113},"commonTop":["Headache","COVID-19","Upper respiratory tract infection","Nausea","Diarrhoea"]}}